Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume $1.01 -0.02 (-1.46%) Closing price 03:59 PM EasternExtended Trading$1.02 +0.01 (+0.49%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enlivex Therapeutics Short Interest DataEnlivex Therapeutics (ENLV) has a short interest of 51,800 shares. This marks a -73.64% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 259,582 shares to cover all short positions.Current Short Interest51,800 sharesPrevious Short Interest196,500 sharesChange Vs. Previous Month-73.64%Dollar Volume Sold Short$94.28 thousandShort Interest Ratio0.1 Days to CoverLast Record DateAugust 15, 2025Outstanding Shares23,651,000 sharesPercentage of Shares Shorted0.22%Today's Trading Volume234,814 sharesAverage Trading Volume259,582 sharesToday's Volume Vs. Average90% Short Selling Enlivex Therapeutics? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/202551,800 shares $94.28 thousand -73.6%N/A0.1 $1.82 7/31/2025196,500 shares $292.79 thousand -33.3%0.9%1.2 $1.49 7/15/2025294,400 shares $362.11 thousand +51.7%N/A3.6 $1.23 6/30/2025194,100 shares $217.39 thousand +157.8%0.9%2.6 $1.12 6/15/202575,300 shares $68.15 thousand -23.6%0.4%1.1 $0.91 5/31/202598,600 shares $94.99 thousand -18.8%0.5%1.3 $0.96 5/15/2025121,400 shares $125.04 thousand -11.3%0.6%1 $1.03 4/30/2025136,900 shares $139.64 thousand +43.1%N/A1.1 $1.02 4/15/202595,700 shares $85.32 thousand -8.3%0.5%0.8 $0.89 3/31/2025104,400 shares $101.29 thousand -17.9%0.6%0.8 $0.97 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/15/2025127,100 shares $155.06 thousand +11.0%0.7%0.9 $1.22 2/28/2025114,500 shares $137.40 thousand +8.9%0.6%0.5 $1.20 2/15/2025105,100 shares $110.36 thousand -11.5%0.6%0.5 $1.05 1/31/2025118,800 shares $130.68 thousand -3.4%N/A0.6 $1.10 1/15/2025123,000 shares $141.45 thousand -1.8%N/A0.5 $1.15 12/31/2024125,200 shares $146.48 thousand -41.2%N/A0.5 $1.17 12/15/2024212,900 shares $255.48 thousand -0.9%N/A0.9 $1.20 11/30/2024214,800 shares $244.87 thousand +116.5%N/A0.9 $1.14 11/15/202499,200 shares $106.14 thousand -38.0%N/A0.7 $1.07 10/31/2024160,100 shares $216.14 thousand +58.7%N/A1.4 $1.35 10/15/2024100,900 shares $156.40 thousand -3.5%N/A1.1 $1.55 9/30/2024104,600 shares $175.73 thousand -23.1%N/A1.4 $1.68 9/15/2024136,100 shares $213.68 thousand +43.9%N/A1.9 $1.57 8/31/202494,600 shares $122.98 thousand +26.6%N/A1.9 $1.30 8/15/202474,700 shares $91.13 thousand -11.7%N/A1.3 $1.22 7/31/202484,600 shares $113.36 thousand -27.4%N/A1.4 $1.34 7/15/2024116,500 shares $164.27 thousand -0.6%N/A1.6 $1.41 6/30/2024117,200 shares $166.42 thousand -16.8%N/A0.7 $1.42 6/15/2024140,800 shares $205.57 thousand -10.5%N/A0.8 $1.46 5/31/2024157,300 shares $213.93 thousand -31.8%N/A0.9 $1.36 5/15/2024230,600 shares $327.45 thousand -12.4%N/A1.3 $1.42 4/30/2024263,200 shares $439.54 thousand -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362.31 thousand +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895.96 thousand -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703.59 thousand +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481.18 thousand -6.6%N/A1.6 $3.21 1/31/2024160,500 shares $449.40 thousand -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533.53 thousand +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378.81 thousand +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145.51 thousand -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202.58 thousand -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194.43 thousand -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157.47 thousand +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147.63 thousand -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179.96 thousand +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206.20 thousand +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252.15 thousand -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303.54 thousand +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290.82 thousand +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248.95 thousand +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268.25 thousand -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362.24 thousand +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316.33 thousand -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359.07 thousand -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369.77 thousand -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396.92 thousand -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588.59 thousand +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577.63 thousand -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652 thousand +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673.46 thousand -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775.70 thousand -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796.51 thousand -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753.64 thousand -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779.22 thousand -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $997.00 thousand +16.9%N/A9 $4.58 11/15/2022186,000 shares $894.66 thousand +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797.08 thousand -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805.23 thousand +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811.33 thousand +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959.18 thousand -5.4%N/A3.9 $5.25 8/31/2022193,100 shares $1.01 million -7.0%N/A4.2 $5.25 8/15/2022207,700 shares $1.08 million -9.5%N/A4.4 $5.22 7/31/2022229,600 shares $975.80 thousand -8.4%N/A4 $4.25 7/15/2022250,600 shares $1.23 million -9.8%N/A3.8 $4.91 6/30/2022277,700 shares $1.26 million -2.3%N/A3.5 $4.52 6/15/2022284,300 shares $1.16 million -0.3%N/A3.5 $4.07 5/31/2022285,000 shares $1.43 million -9.2%N/A3.5 $5.01 5/15/2022313,900 shares $1.34 million -9.6%N/A4.1 $4.28 4/30/2022347,200 shares $1.98 million -3.9%N/A4.7 $5.69 4/15/2022361,300 shares $2.67 million +15.0%N/A5.9 $7.39 3/31/2022314,200 shares $1.76 million -2.2%N/A5.3 $5.59 3/15/2022321,300 shares $1.63 million -10.4%N/A5.3 $5.06 2/28/2022358,500 shares $1.92 million -4.0%N/A4.9 $5.35 2/15/2022373,500 shares $1.99 million +2.8%N/A4.7 $5.34 1/31/2022363,200 shares $1.94 million +8.2%N/A4.2 $5.34 1/15/2022335,700 shares $1.97 million -8.3%N/A3.7 $5.87 12/31/2021365,900 shares $2.29 million +0.1%N/A4.2 $6.25 12/15/2021365,400 shares $2.40 million -3.6%N/A4.4 $6.56 11/30/2021379,000 shares $2.65 million +7.0%N/A5 $7.00 11/15/2021354,200 shares $2.91 million +9.9%N/A3.5 $8.21 10/29/2021322,200 shares $2.65 million +4.5%N/A1 $8.24 10/15/2021308,300 shares $2.86 million -13.0%N/A0.9 $9.28 9/30/2021354,300 shares $3.50 million -8.0%N/A1.1 $9.88 9/15/2021385,200 shares $4.21 million -8.0%N/A1.2 $10.92 8/31/2021418,500 shares $5.80 million +114.2%N/A1.3 $13.86 8/13/2021195,400 shares $1.99 million +38.0%N/A0.7 $10.17 7/30/2021141,600 shares $1.08 million No Change1.2%2.1 $7.60 7/15/2021141,600 shares $1.07 million +0.9%1.2%1.8 $7.54 6/30/2021140,400 shares $1.25 million +4.0%1.2%1.6 $8.90 6/15/2021135,000 shares $1.32 million +14.9%1.1%1.5 $9.80 5/28/2021117,500 shares $1.10 million -28.6%1.0%1.1 $9.37 5/14/2021164,500 shares $1.42 million +26.4%N/A1.1 $8.61 4/30/2021130,100 shares $1.57 million +94.2%N/A0.3 $12.10 4/15/202167,000 shares $725.61 thousand -18.8%N/A0.2 $10.83 3/31/202182,500 shares $874.50 thousand -17.6%N/A0.2 $10.60 3/15/2021100,100 shares $1.44 million +5.2%1.0%0.2 $14.40 2/26/202195,200 shares $1.44 million +64.4%1.1%0.2 $15.11 2/12/202157,900 shares $1.22 million -76.6%0.7%0.1 $21.09 1/29/2021246,900 shares $2.93 million +13.8%3.2%0.7 $11.85 1/15/2021217,000 shares $2.23 million +7.1%2.9%1 $10.29 12/31/2020202,600 shares $1.87 million -24.9%2.7%0.7 $9.22 12/15/2020269,700 shares $2.65 million +165.2%3.5%0.2 $9.83 11/30/2020101,700 shares $876.65 thousand -38.2%1.3%0.1 $8.62 11/15/2020164,600 shares $1.53 million -13.1%2.2%0.1 $9.28 10/30/2020189,500 shares $2.23 million -53.7%2.5%0.2 $11.75 10/15/2020408,900 shares $5.41 million +1,497.3%5.4%0.4 $13.23 9/30/202025,600 shares $152.06 thousand +22.5%0.3%0 $5.94 9/15/202020,900 shares $108.26 thousand -57.1%0.3%0.3 $5.18 ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 15th, traders have sold 51,800 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. Which institutional investors are shorting Enlivex Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enlivex Therapeutics: Group One Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a drop in short interest in August. As of August 15th, there was short interest totaling 51,800 shares, a drop of 73.6% from the previous total of 196,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enlivex Therapeutics: Atossa Genetics Inc. (2.83%), Elutia Inc. (0.09%), XBiotech Inc. (1.56%), Anixa Biosciences Inc (1.31%), Celularity, Inc. (11.16%), Ovid Therapeutics (2.54%), Cardiol Therapeutics Inc. (2.38%), Oramed Pharmaceuticals Inc. (0.89%), Vaxart, Inc. (3.26%), CervoMed Inc. (5.53%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Lucid Group, Inc. ($8.00 billion), Spotify Technology ($5.48 billion), AppLovin Corporation ($5.11 billion), Reddit Inc. ($5.02 billion), Coinbase Global, Inc. ($3.99 billion), Charter Communications, Inc. ($3.89 billion), Live Nation Entertainment, Inc. ($3.18 billion), Seagate Technology Holdings PLC ($2.59 billion), ResMed Inc. ($2.55 billion), and Rocket Lab Corporation ($2.52 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is August, 15 2025. More Short Interest Resources from MarketBeat Related Companies Atossa Genetics Short Squeeze Elutia Short Squeeze XBiotech Short Squeeze Anixa Biosciences Short Squeeze Celularity Short Squeeze Ovid Therapeutics Short Squeeze Cardiol Therapeutics Short Squeeze Oramed Pharmaceuticals Short Squeeze Vaxart Short Squeeze CervoMed Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
